You can read the abstract of this article at LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM)
Research shows that synephrine has been associated with adverse cardiovascular effects
Palatable carriers are mono and poly saccharides to ensure energy supply is steady and not heating Contains Glutamine and Prebiotics to help stabilise the gut during stressful Bicarbonate helps to buffer the metabolic pH for maximise body and muscle ELITE EQUINE TURBO BOOST PASTE For RACE HORSES, SHOW JUMPERS, POLO HORSES, ENDURANCE HORSES and racing greyhounds
A contrast-enhanced CT scan can help make the diagnosis in these situations, because paragangliomas become intensely enhanced compared with nerve sheath tumors that may or may not become enhanced
8-hydroxy-2-deoxyguanosine levels and cardiovascular disease: A systematic review and meta-analysis of the literature
These bioactive compounds are categorised based on their mechanisms of action
